Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: The glucagon-like peptide-1 receptor agonist, semaglutide, improved health status and reduced body weight in patients with obesity-related heart failure (HF) with preserved ejection fraction (HFpEF) in the STEP-HFpEF (Semaglutide Treatment Effect in People with Obesity and HFpEF) program. Whether benefits were due to mechanical unloading or effects on HF pathobiology is uncertain.
Objectives: This study sought to determine if semaglutide 2.4 mg reduced N-terminal pro-B-type natriuretic peptide (NT-proBNP) in patients with obesity-related HFpEF and compare treatment responses by baseline NT-proBNP.
Methods: This was a prespecified secondary analysis of pooled data from 2 double-blind, placebo-controlled, randomized trials (STEP-HFpEF [Research Study to Investigate How Well Semaglutide Works in People Living With Heart Failure and Obesity] and STEP-HFpEF DM [Research Study to Look at How Well Semaglutide Works in People Living With Heart Failure, Obesity and Type 2 Diabetes]) testing effects of semaglutide in patients with obesity-related HFpEF. The main outcomes were change in NT-proBNP at 52 weeks and change in the dual primary endpoints of Kansas City Cardiomyopathy Questionnaire Clinical Summary Score and body weight by baseline NT-proBNP.
Results: In total, 1,145 patients were randomized. Semaglutide compared with placebo reduced NT-proBNP at 52 weeks (estimated treatment ratio: 0.82; 95% CI: 0.74-0.91; P = 0.0002). Improvements in health status were more pronounced in those with higher vs lower baseline NT-proBNP (estimated difference: tertile 1: 4.5 points, 95% CI: 0.8-8.2; tertile 2: 6.2 points, 95% CI: 2.4-10.0; tertile 3: 11.9 points, 95% CI: 8.1-15.7; P interaction = 0.02; baseline NT-proBNP as a continuous variable: P interaction = 0.004). Reductions in body weight were consistent across baseline NT-proBNP levels (P interaction = 0.21).
Conclusions: In patients with obesity-related HFpEF, semaglutide reduced NT-proBNP. Participants with higher baseline NT-proBNP had a similar degree of weight loss but experienced larger reductions in HF-related symptoms and physical limitations with semaglutide than those with lower NT-proBNP.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jacc.2024.04.022 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Frailty and Semaglutide in Obesity-Related HFpEF: Another STEP in the Right Direction.
JACC Heart Fail
August 2025
Lawson Research Institute, London, Ontario, Canada; Department of Medicine, Western University, London, Ontario, Canada.
Semaglutide in Heart Failure With Preserved Ejection Fraction: Emerging Evidence and Clinical Implications.
Cureus
July 2025
Internal Medicine, Monmouth Medical Center, Long Branch, USA.
Heart failure with preserved ejection fraction (HFpEF) poses a growing public health challenge, characterized by limited therapeutic options and a high burden of comorbid obesity and type 2 diabetes (T2D). Semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA), has shown promise in addressing these comorbidities, offering potential benefits in obesity-related HFpEF. We analyzed key clinical trials, including SUSTAIN 6, PIONEER 6, STEP HFpEF, STEP HFpEF DM, and supportive studies on glucagon-like peptide receptor agonists (GLP-1 RAs) and sodium-glucose cotransporter 2 (SGLT2) inhibitors, alongside mechanistic insights into semaglutide's metabolic, anti-inflammatory, and decongestive effects.
View Article and Find Full Text PDFSpecific targeting of adipose tissue metabolism is superior to caloric restriction in treating obesity-related HFpEF.
Cardiovasc Diabetol
July 2025
Department of Cardiology, Medical University of Graz, Auenbruggerplatz 15, 8036, Graz, Austria.
Obesity is a modifiable major driver of heart failure with preserved ejection fraction (HFpEF), the most common and rapidly increasing form of heart failure. Current metabolic therapies, such as caloric restriction and incretin-based drugs, have shown promise in treating obesity-related HFpEF. However, these interventions neither specifically nor selectively improve adipose tissue metabolism, which is a key etiological factor in HFpEF that may offer a pathway to safer and more effective treatment strategies.
View Article and Find Full Text PDFCirculating Immune Cell Signature Analysis in HFpEF Across Species.
Circ Res
August 2025
Klinik und Poliklinik für Kardiologie, Universitätsklinikum Leipzig, Leipzig, Germany (J.M.K., S.E., K.E.K., I.M.-K., S.C.S., C.M., S.F.H., S.G., R.W., U.L., J.-N.B.).
Background: Heart failure with preserved ejection fraction (HFpEF) is a heterogeneous clinical picture that is closely related to extracardiac comorbidities such as obesity, hypertension, and diabetes and is associated with chronic, low-grade systemic inflammation. Previous studies on myocardial biopsies of patients with HFpEF showed intramyocardial inflammatory activity, suggesting that the inflammatory processes in HFpEF are predominantly systemic and exhibit compartment-specific patterns.
Methods: We performed single-cell RNA sequencing of peripheral blood mononuclear cells of patients with HFpEF (n=6), patients with heart failure with reduced ejection fraction (HFrEF, n=8), and healthy controls (n=7), taking obesity status into account.
Impact of Body Mass Index, Central Adiposity, and Weight Loss on the Benefits of Tirzepatide in HFpEF: The SUMMIT Trial.
J Am Coll Cardiol
July 2025
Baylor University Medical Center, Dallas, Texas, USA; Imperial College, London, United Kingdom.
Background: The SUMMIT trial showed that the long-acting glucose-dependent insulinotropic polypeptide receptor and glucagon-like peptide 1 receptor agonist tirzepatide decreased the risk of cardiovascular death or worsening heart failure (HF) in patients with obesity-related heart failure with preserved ejection fraction (HFpEF). Effects may differ by baseline obesity severity, distribution, or magnitude of weight loss.
Objectives: In this analysis, the authors compared baseline characteristics and effects of tirzepatide on primary and other endpoints according to baseline obesity severity and distribution, and we explored relationships between degree of weight loss achieved and outcomes.